Abstract :

This study was aimed to assess and review the current practice of screening of HIV in TB patients within NHRD Welisara hospital against the recommended standard practice by the National Guideline and the cross-sectional study was conducted on newly diagnosed tuberculosis patients. Simple random sampling was used to collect data from a sample size of 163, with retrospective data gathered from patient ward records. Data quality was enhanced by reviewing clinic and laboratory records, and a secure Excel spreadsheet was maintained for data management.

Results: Data indicated that 12.3% (n=20) lacked documentation for HIV testing. Of the 143 patients tested, only 43.4% (n=62) were tested while in the ward; others were tested at follow-up clinics. The average time from TB confirmation to HIV testing was 4.8 days (range: 0 to 36 days). Though average post-TB diagnosis hospital stay was 20.9 days (range: 0 to 129 days) for HIV tested patients, those without HIV testing had an average stay of 12 days (range: 0 to 40 days).

The primary reason for not undergoing HIV testing was patient transfer, but with an average ward stay of 14.6 days post-TB diagnosis. Other factors included patient death, disappearance, or leaving against medical advice. Notably, four patients were discharged without HIV testing, having stayed 3 to 11 days post-TB diagnosis. Most patients (51.7%, n=74) were tested at the NHRD laboratory, while 39.9% (n=57) were tested at an STD clinic, and only 5.6% underwent RDTs in the ward.

Conclusion: Those without HIV testing had prolonged hospital stays, suggesting missed opportunities. Underutilization of RDTs by ward staff needs attention. Incorporating HIV test results into the discharge checklist may prevent these oversights. Therefore, findings will be presented to the director-NHRD aiming to initiate a discussion and create an audit cycle.

---

Keywords :

HIV test, Newly diagnosed tuberculosis, Welisara Sri Lanka.

---

References :

1. Bayer R, Edington C. (2009). HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law. 2009;34(3)
2. Branson, BM., Handsfield, HH., Lampe, MA., Janssen, RS., Taylor, AW., Lyss, SB., et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.
3. ECDC/WHO. Tuberculosis surveillance and monitoring report in Europe 2019. 2019.
4. ECDC/WHO. Tuberculosis surveillance and monitoring in Europe 2023. 2023. 5. UNAIDS. Fact sheet—world tuberculosis day 2022. 2022
5. ECDC/WHO. Tuberculosis surveillance and monitoring in Europe 2022. 2022.
6. ECDC/WHO. Tuberculosis surveillance and monitoring in Europe 2023. 2023. 5. UNAIDS. Fact sheet—world tub
7. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland 2022. 2023
8. Sendagire I, Schreuder I, Mubiru M, van der Loeff MS, Cobelens F, KondeLule J, Low HIV. Testing rates among tuberculosis patients in Kampala, Uganda. BMC Public Health. 2010;10(1):177
9. Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E,
10. Global tuberculosis report 2023. 2023.
11. World Health Organization. Global HIV Programme. HIV data and statistics, https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/ strategic-information/hiv-data-and-statistics (2021, accessed 15 April 2023).
12. World Health Organization. Tuberculosis & HIV, www.who.int/teams/globalhiv-hepatitis-and-stis-programmes/hiv/treatment/tuberculosis-hiv (2020, accessed 15 Aprily 2023). 3. Nanta S, Kantipong P, Pathipvanich P, et al. Screening scheme development
13. Global tuberculosis report 2017. Geneva: World health organization; 2017. Disponible en: http://www.whoint/tb/publications/global_report/en/. Accessed 21 Feb 2018. 2. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV
14. Global tuberculosis report 2022. 2022
15. Tuberculosis: Perfiles de países 2017. World Health Organization, Geneva; 2017. Disponible en: http://www.who.int/tb/country/data/profiles/ es/ Accessed 21 February, 2018.
16. Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., … & Sanne, I. (2011). Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine, 365(16), 1482-1491
17. Kigozi, G., Heunis, C., Chikobvu, P., van den Berg, H., & Meulemans, H. (2021). Predictors of uptake of human immunodeficiency virus testing by tuberculosis patients in South Africa. Journal of Public Health in Africa, 12(3), 1553.
18. Gupta, A., Wood, R., Kaplan, R., Bekker, L. G., & Lawn, S. D. (2017). Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: Comparison with rates in the community. Journal of Clinical Infectious Diseases, 64(6), 773-780.
19. Kigozi, G., Heunis, C., Chikobvu, P., van den Berg, H., & Meulemans, H. (2021). Predictors of uptake of human immunodeficiency virus testing by tuberculosis patients in South Africa. Journal of Public Health in Africa, 12(3), 1553.
20. Dileka WS, Weerasinghe G, Samaraweera G, Rathnayaka T, Wijesekara KA, Widanage N, Rajapakse LI, Perera HP, Jayakody CJ, Perera KY. HIV Prevalence among Medical Inward Patients in the National Hospital of Sri Lanka (NHSL) with the Assessment of Patient Acceptance, the Feasibility and Challenges of the Hospital Based Rapid HIV Diagnostic Test. Sri Lanka Journal of Sexual Health and HIV Medicine. 2020 Dec 31;6.